Table 1. Phenotypic drug susceptibility test results among patients enrolled in the study.
| Drug susceptibility | n/N | % |
|---|---|---|
| Drug susceptibility test for first-line drug (n=402 with DST available) | ||
| Sensitive to first-line four drugs | 306/402 | 76.1 |
| Mono-resistance to INH | 44/402 | 10.9 |
| Mono-resistance to RMP | 1/402 | 0.2 |
| Mono-resistance to EMB | 0/402 | 0.0 |
| Mono-resistance to PZA | 3/402 | 0.7 |
| Poly-resistance to first-line drugs | 2/402 | 0.5 |
| Multidrug resistance (INH and RMP) | 46/402 | 11.4 |
| Extensively drug-resistance | 4/402 | 1.0 |
| Any resistance to INH | 92/402 | 22.9 |
| Any resistance to RMP | 47/402 | 11.7 |
| Any resistance to EMB | 21/402 | 5.2 |
| Any resistance to PZA | 24/402 | 6.0 |
| Drug susceptibility test for second-line drug (n=46 with MDR-TB) | ||
| Any resistance to EMB | 20/46 | 43.5 |
| Any resistance to PZA | 20/46 | 43.5 |
| Any resistance to RFB | 41/46 | 89.1 |
| Any resistance to AMK | 3/45 | 6.7 |
| Any resistance to SM | 29/46 | 63.0 |
| Any resistance to KM | 6/41 | 14.6 |
| Any resistance to CM | 6/46 | 13.0 |
| Any resistance to MXF | 5/41 | 12.2 |
| Any resistance to OFX | 8/46 | 17.4 |
| Any resistance to ETA | 13/46 | 28.3 |
| Any resistance to PAS | 5/46 | 10.9 |
| Any resistance to LZD | 0/41 | 0.0 |
| Any resistance to CLO | 0/5 | 0.0 |
Abbreviations: AMK, amikacin; CLO, clofazimine; CM, capreomycin; DST, drug susceptibility test; EMB, ethambutol; ETA, ethionamide; INH, isoniazid; KM, kanamycin; LZD, linezolid; MDR, multidrug-resistant; MXF, moxifloxacin; OFX, ofloxacin; PAS, p-aminosalicylic acid; PZA, pyrazinamide; RFB, rifabutin; RMP, rifampin; SM streptomycin; TB, tuberculosis